- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01871818
A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients (REHABMUSCLE)
October 22, 2018 updated by: Assistance Publique - Hôpitaux de Paris
A Multi-centre Randomised Controlled Trial to Compare the Effectiveness of Two Rehabilitation Programs in Patients With Multiple Sclerosis.
The purpose of this study was to compare the effectiveness of two rehabilitation programs (one month) in patients with multiple sclerosis.
The first program is combined with physiotherapy, endurance training and resistance training.
The second one is physiotherapy in private practice.
Another purpose is to assess the length of the benefits of the combined program.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study will include 240 patients with a diagnosis of Multiple Sclerosis and with an Expanded Disability Status Scale ≤ 5. Patients will be divided into 2 groups, according to a randomization design.
At recruitment (J0), after rehabilitation (M1) and at follow up (M3 and M6) each patient will be tested for the primary and secondary outcomes.
Study Type
Interventional
Enrollment (Anticipated)
240
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hauts DE Seine
-
Garches, Hauts DE Seine, France, 92380
- Physical medicine and rehabilation Department, Hôpital RAYMOND POINCARE
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 year or over
- Able to walk independently without use of assistance 200 meters Expanded Disability Status Scale ≤5
- No relapse within the last three months
- No current or recent (six months) participation in intensive rehabilitation
- No recent modification (six months) of medications for MS
- Patients who received and signed information and informed consent
Exclusion Criteria:
- Cognitive impairments which could interfere with the ability to fully engage the rehabilitation program.
- Recent involvement (three months) in another interventional research study
- A complicating medical condition or orthopedic diagnosis that limits rehabilitation
- Cardiac or respiratory disease that interfere with endurance training
- Patient with safety measure
- Pregnant women, breastfeeding
- No affiliation to a social security
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Combined program
Combined program with physiotherapy, endurance training and resistance training. 120 patients will receive this combined program |
Combined program with physiotherapy, endurance training and resistance training
|
|
Active Comparator: Physiotherapy
Active comparator: physiotherapy in private practice 120 patients will receive this usual rehabilitation
|
Physiotherapy in private practice
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
6 Minute Walk Test
Time Frame: 6 Minutes
|
6 Minute Walk Test (6MWT) at the end of the rehabilitation program (Time Frame : at one month M1)
|
6 Minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional tests
Time Frame: 20 Minutes
|
Functional tests: 10 meters Walk Test, Timed up and go test, Time to ascend and descend stairs, 6 Minute Walk Test Time frame:10 meters walk test = 2 min ; time up and going test= 4 min ; Time to ascend and descend stairs = 4 min ; et 6min walk = 6min |
20 Minutes
|
|
Aerobic capacity
Time Frame: 1h
|
Aerobic capacity (V02 max)
|
1h
|
|
Strength and fatigue of the knee flexors and extensors
Time Frame: 45 min
|
Assessment of maximal voluntary strength using an isokinetic dynamometer or assessment of maximal voluntary strength using the 1-RM estimation
|
45 min
|
|
Clinical assessment
Time Frame: 45 min
|
Spasticity assessment (Modified Ashworth Scale), passive range of motion of lower limb joint, lower limb strength (Medical Research Council scale), self questionnaire of pain.
|
45 min
|
|
Balance (Berg Balance scale) and postural control assessment
Time Frame: 15 min
|
15 min
|
|
|
Quality of Life assessment
Time Frame: 55 min
|
Quality of Life assessed by self-reported questionnaire (SEP -59; EQ-5D), mood (HAD), MSIS-29, auto-questionnaire estimating the fatigue (Fatigue Severity Scale, Modified Fatigue Impact Scale)
|
55 min
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Djamel Bensmail, MD, Physical medicine and rehabilation Department, Hôpital RAYMOND POINCARE, 92380 Garches, France
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2013
Primary Completion (Actual)
April 1, 2017
Study Completion (Actual)
October 1, 2017
Study Registration Dates
First Submitted
May 24, 2013
First Submitted That Met QC Criteria
June 4, 2013
First Posted (Estimate)
June 7, 2013
Study Record Updates
Last Update Posted (Actual)
October 23, 2018
Last Update Submitted That Met QC Criteria
October 22, 2018
Last Verified
November 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P110116
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Combined program
-
Yeditepe UniversityThe Scientific and Technological Research Council of TurkeyCompletedMultiple Sclerosis | Multiple Sclerosis (MS) - Relapsing-remittingTurkey (Türkiye)
-
University of ÉvoraSão João de Deus School of Nursing; Horizon 2020 - Portugal 2020 (ALT20-03-0145-FEDER-000007...CompletedFallers | High Risk of FallingPortugal
-
Bartın UnıversityNot yet recruitingLearning DisabilitiesTurkey (Türkiye)
-
Necmettin Erbakan UniversityCompleted
-
Ondokuz Mayıs UniversityNot yet recruitingUrinary Incontinence | Postmenopausal
-
Ana Lista PazUniversidade da Coruña; Complexo Hospitalario Universitario de A CoruñaNot yet recruiting
-
University of California, San DiegoNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Fenerbahce UniversityRecruitingSleep Wake Disorders | Autonomic Nervous System Diseases | Menopausal Symptoms | PostmenopausalTurkey (Türkiye)
-
Pusan National University Yangsan HospitalCompletedGhrelinKorea, Republic of
-
University of AlicanteActive, not recruitingBreast Cancer SurvivorsSpain